Ligand Promacta data should support approval, says Roth Capital

theflyonthewall.com

After GlaxoSmithKline (GSK) announced that Promacta, which was discovered by itself and Ligand (LGND), achieved its primary endpoint of improved platelet counts in pediatric patients with cITP, Roth Capital thinks the data should support approval of the drug. The firm reiterates a $92 price target and Buy rating on Ligand.

Rates

View Comments (0)